The headline reads as positive (90% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › LGND
Ligand Pharmaceuticals Inc (LGND) stock analysis
BUY 60% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Ligand Pharmaceuticals Inc (LGND) BUY with 60% confidence at a price of $318.41. That means most of the technical, fundamental, money-flow and news signals point to upside.
Analysed price$318.41
Technical picture
The 14-day RSI is 61, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.5x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $326.63 and the swing low is $175.89; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 1.53, which looks reasonably priced for its growth.
The company reports a profit margin of 67.9% and revenue growth of +33.7%.
In its latest quarter it earned $2.37 per share, which beat the $1.95 analysts expected, with revenue +33.7% year over year.
Wall Street's average rating is 1.3 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $345.75.
Trade plan from the model
The model's long / bullish plan uses an entry near $318.41, a target of $345.75 (+8.6%) and a stop-loss at $297.06 (-6.7%).
That is a reward-to-risk ratio of about 1.3 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Nov 19, 2026 whatever the price does.
Entry$318.41
Target$345.75
Stop-loss$297.06
Reassess byNov 19, 2026
Research notes
LGND’s bull case is accelerating, high-margin royalty growth: Q3 royalty revenue rose 51% year over year to $70.3 million, helped by Filspari, Ohtuvayre, and the XOMA portfolio acquisition, while adjusted 2026 EPS guidance increased to $9.50–$9.75. The bear case is valuation and concentration risk after a roughly fivefold three-year share-price gain, alongside XOMA integration costs—G&A rose 156%—and dependence on a relatively small number of major royalty streams. The major recent catalyst is today’s Q3 report and raised EPS outlook; additional upside could come from as many as seven pivotal trial readouts through 2027, beginning with the February 28, 2027 FDA decision for QTORIN rapamycin.
The model's one-paragraph read
Leans BUY — composite score +0.60 (BUY). Technicals: RSI 60.64, MACD bullish, price above SMA50. Fundamentals: PEG 1.53, margin 67.9%, revenue growth 33.7%. Financial results: YoY revenue +33.7%, last EPS surprise +21.5%. Smart Money Concepts: ranging / no clear structure. FinGPT news read: positive. Internet research: LGND’s **bull case** is accelerating, high-margin royalty growth: Q3 royalty revenue rose 51% year over year to $70.3 million, helped by Filspari, Ohtuvayre, and the XOMA portfolio acquisition, while adjusted 2026 EPS guidance increased to $9.50–$9.75. The **bear case** is valuation and concentration risk after a roughly fivefold three-year share-price gain, alongside XOMA integration costs—G&A rose 156%—and dependence on a relatively small number of major royalty streams. The major recent catalyst is today’s Q3 report and raised EPS outlook; additional upside could come from as many as seven pivotal trial readouts through 2027, beginning with the February 28, 2027 FDA decision for QTORIN rapamycin. Suggested levels: entry $318.41, target $345.75, stop-loss $297.06, exit by 2026-11-19 (21-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for LGND
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | BUY | 60% | $318.41 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on LGND
Oct 29, 2026 · Ligand's Royalty Engine Drives A Clean EPS Beat And Second Guidance Raise, But Held Revenue Outlook And A Heavier Balance Sheet Temper The Story
- Oct 29, 2026: Ligand's Royalty Engine Drives A Clean EPS Beat And Second Guidance Raise, But Held Revenue Outlook And A Heavier Balance Sheet Temper The Story (Earnings Whispers)
- Oct 29, 2026: Ligand Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Frequently asked questions
Is LGND a buy right now?
As of Oct 29, 2026, our automated model rates Ligand Pharmaceuticals Inc (LGND) BUY with 60% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for LGND?
The model's most recent plan targets $345.75 with a stop-loss at $297.06, from an entry near $318.41.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.